Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma.

Chui MH, Doodnauth SA, Erdmann N, Tiedemann RE, Sircoulomb F, Drapkin R, Shaw P, Rottapel R.

Cancer Res. 2019 Nov 1;79(21):5536-5549. doi: 10.1158/0008-5472.CAN-18-3029. Epub 2019 Sep 17.

PMID:
31530568
2.

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma.

Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, Chung KC, Tiedemann RE.

Cancer Cell. 2015 Oct 12;28(4):541-542. doi: 10.1016/j.ccell.2015.09.010. Epub 2015 Oct 12. No abstract available.

3.

Clinical characteristics and early treatment outcomes of follicular lymphoma in young adults.

Gangatharan SA, Maganti M, Kuruvilla JG, Kukreti V, Tiedemann RE, Gospodarowicz MK, Hodgson DC, Sun A, Tsang RW, Pintilie M, Crump M.

Br J Haematol. 2015 Aug;170(3):384-90. doi: 10.1111/bjh.13451. Epub 2015 Apr 22.

PMID:
25904266
4.

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.

Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D, Shi CX, Mantei J, Ahmann G, Gonzales IM, Choudhary A, Valdez R, Camoriano J, Fauble V, Tiedemann RE, Qiu YH, Coombes KR, Cardone M, Braggio E, Yin H, Azorsa DO, Mesa RA, Stewart AK, Tibes R.

Leukemia. 2014 Aug;28(8):1657-65. doi: 10.1038/leu.2014.44. Epub 2014 Jan 23.

5.

Getting to the root of the problem: the causes of relapse in multiple myeloma.

Chan Chung KC, Tiedemann RE.

Expert Rev Anticancer Ther. 2014 Mar;14(3):251-4. doi: 10.1586/14737140.2014.868776. Epub 2014 Jan 8.

PMID:
24397833
6.

Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.

Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, Chung KC, Tiedemann RE.

Cancer Cell. 2013 Sep 9;24(3):289-304. doi: 10.1016/j.ccr.2013.08.009. Erratum in: Cancer Cell. 2015 Oct 12;28(4):541-2.

7.

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.

Schmidt J, Braggio E, Kortuem KM, Egan JB, Zhu YX, Xin CS, Tiedemann RE, Palmer SE, Garbitt VM, McCauley D, Kauffman M, Shacham S, Chesi M, Bergsagel PL, Stewart AK.

Leukemia. 2013 Dec;27(12):2357-65. doi: 10.1038/leu.2013.172. Epub 2013 Jun 11.

8.

Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome.

Tiedemann RE, Zhu YX, Schmidt J, Shi CX, Sereduk C, Yin H, Mousses S, Stewart AK.

Cancer Res. 2012 Feb 1;72(3):757-68. doi: 10.1158/0008-5472.CAN-11-2781. Epub 2011 Dec 6.

9.

Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6.

Tiedemann RE, Zhu YX, Schmidt J, Yin H, Shi CX, Que Q, Basu G, Azorsa D, Perkins LM, Braggio E, Fonseca R, Bergsagel PL, Mousses S, Stewart AK.

Blood. 2010 Feb 25;115(8):1594-604. doi: 10.1182/blood-2009-09-243980. Epub 2009 Dec 7.

10.

Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo.

Tiedemann RE, Schmidt J, Keats JJ, Shi CX, Zhu YX, Palmer SE, Mao X, Schimmer AD, Stewart AK.

Blood. 2009 Apr 23;113(17):4027-37. doi: 10.1182/blood-2008-09-179796. Epub 2008 Dec 18.

11.

Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity.

Tiedemann RE, Mao X, Shi CX, Zhu YX, Palmer SE, Sebag M, Marler R, Chesi M, Fonseca R, Bergsagel PL, Schimmer AD, Stewart AK.

J Clin Invest. 2008 May;118(5):1750-64. doi: 10.1172/JCI34149.

12.

Genetic aberrations and survival in plasma cell leukemia.

Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA, Chng WJ, Ketterling RP, Gertz MA, Henderson K, Greipp PR, Dispenzieri A, Lacy MQ, Rajkumar SV, Bergsagel PL, Stewart AK, Fonseca R.

Leukemia. 2008 May;22(5):1044-52. doi: 10.1038/leu.2008.4. Epub 2008 Jan 24.

13.

Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma.

Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY, Stewart AK.

Blood. 2007 Jun 15;109(12):5430-8. Epub 2007 Mar 1.

PMID:
17332241
14.

The superantigen streptococcal pyrogenic exotoxin C (SPE-C) exhibits a novel mode of action.

Li PL, Tiedemann RE, Moffat SL, Fraser JD.

J Exp Med. 1997 Aug 4;186(3):375-83.

16.

Isolation of HLA-DR1.(staphylococcal enterotoxin A)2 trimers in solution.

Tiedemann RE, Urban RJ, Strominger JL, Fraser JD.

Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12156-9.

17.

Staphylococcal enterotoxin A has two cooperative binding sites on major histocompatibility complex class II.

Hudson KR, Tiedemann RE, Urban RG, Lowe SC, Strominger JL, Fraser JD.

J Exp Med. 1995 Sep 1;182(3):711-20.

Supplemental Content

Loading ...
Support Center